WebObjectives: To describe the clinical activity of metronomic cyclophosphamide in a population of patients with recurrent ovarian cancer, and to identify predictors of clinical response. Methods: We retrospectively reviewed all patients treated at our institution with oral metronomic cyclophosphamide for relapsed ovarian cancer between January … WebApr 14, 2024 · Survival outcomes for patients with advanced ovarian cancer remain poor despite advances in chemotherapy and surgery. Platinum-based systemic chemotherapy …
Addition of Bevacizumab to Pembrolizumab Improves Responses …
WebFor example, PARP inhibitor and anti-angiogenic agent (eg, bevacizumab) are now established as maintenance therapy after the first-line chemotherapy. 8,9 Immunotherapy has had limited success in ovarian cancer owing to predominantly “cold” or immunosuppressive nature of most epithelial ovarian cancer. WebMar 18, 2024 · Emese Zsiros, MD, PhD. Women with recurrent ovarian cancer treated with the combination of pembrolizumab (Keytruda), bevacizumab (Avastin), and metronomic … see git commit history
Ovarialkarzinom Medikamentöse Therapie des Ovarialkarzinoms …
WebJan 6, 2024 · The study, PRESERVE-004, is evaluating the combination in adults with platinum-resistant ovarian cancer that has progressed on a prior therapy containing Avastin (bevacizumab). The researchers plan on enrolling approximately 58 patients across 20 cancer centers across the United States. WebSep 21, 2016 · Vascular endothelial growth factor (VEGF) plays an important role in the biology of ovarian cancer (OC). Inhibitors of VEGF suppress tumor growth in OC models. Metronomic chemotherapy, defined as frequent administration of low doses of cytotoxic chemotherapy, suppresses tumor growth, possibly by inhibiting angiogenesis. WebAvastin, in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, is approved to treat platinum-resistant recurrent epithelial ovarian, fallopian tube or … see git branch history